专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008134076A1 METHODS FOR REDUCING VIRAL LOAD IN HIV-1-INFECTED PATIENTS 审中-公开
标题翻译：减少HIV-1感染患者病毒载量的方法
公开(公告)号：WO2008134076A1
公开(公告)日：2008-11-06
申请号：PCT/US2008/005564
申请日：2008-04-30
申请人： PROGENICS PHARMACEUTICALS, INC. , OLSON, William, C. , MADDON, Paul, J. , PEVEAR, Daniel, C. , ISRAEL, Robert, J. , MURGA, Jose, D.
发明人： OLSON, William, C. , MADDON, Paul, J. , PEVEAR, Daniel, C. , ISRAEL, Robert, J. , MURGA, Jose, D.
IPC分类号： G01N33/53
CPC分类号： C07K16/2866 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2812 , C07K2317/21 , C07K2317/24 , C07K2317/76
摘要： This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves achieves an average maximum decrease of viral load in the subject of at least 1.83 log 10 to 2.5 log 10 at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log 10 at about nine days following administration of the CCR5 receptor antagonist. The viral load reducing dose results in a suppression of mean viral load by 1.0 log 10 within about four days following administration of the CCR5 receptor antagonist, and suppression of viral load in the subject persists at or below a level of reduction of 1.0 log 10 for about two to three weeks. This invention also provides a method of elevating CD4+ cell count in an HIV-1 -infected human subject which comprises administering to the subject at a predefined interval an effective HIV-1 viral load-reducing dose of a humanized antibody designated PRO 140, or an anti-CCR5 receptor monoclonal antibody.
摘要翻译：本发明提供了一种降低HIV-1感染的人受试者中的病毒载量的方法，其包括向受试者施用有效的HIV-1病毒载量减少剂量的CCR5受体拮抗剂，例如命名为PRO 140的人源化抗体或抗 - -CCR5受体单克隆抗体，其中所述病毒负荷降低剂量达到达到在约1小时至少1.83log 10至2.5log 10/10的受试者中病毒载量的平均最大降低在施用CCR5受体拮抗剂后十天，并且其中病毒载量降低剂量在施用CCR5受体拮抗剂后约9天进一步达到1.7log 10的平均病毒载量降低。在施用CCR5受体拮抗剂后约4天内，病毒载量降低剂量导致平均病毒载量的抑制为1.0log 10，并且受试者的病毒载量的抑制持续在或低于一个水平减少1.0log 10，持续约2-3周。本发明还提供了一种在HIV-1感染的人受试者中提高CD4 +细胞计数的方法，其包括以预定间隔向所述受试者施用命名为PRO 140的人源化抗体的有效的HIV-1病毒载量降低剂量，或抗CCR5受体单克隆抗体。

2. 发明申请

WO2002082722A3 ALTERNATE ROUTING OF VOICE COMMUNICATION IN A PACKET-BASED NETWORK 审中-公开
公开(公告)号：WO2002082722A3
公开(公告)日：2002-10-17
申请号：PCT/US2002/011076
申请日：2002-04-08
申请人： GENUITY INCORPORATION , MUSSMAN, Harry, Edward , MCCABE, John, Joseph , MCGUIGAN, David, Frederick , ISRAEL, Robert, Keller , SPOREL, Eric, Richard
发明人： MUSSMAN, Harry, Edward , MCCABE, John, Joseph , MCGUIGAN, David, Frederick , ISRAEL, Robert, Keller , SPOREL, Eric, Richard
IPC分类号： H04L29/06
摘要： A method for performing alternate and therefore least cost routing in distributed H.323 Voice over IP (VoIP) networks is provided. With this method, the VoIP network consists of a hierarchy of gatekeeper (GK) functions to provide alternate routing, network element redundancy, and scalability. The alternate routing function is performed by a directory gatekeeper with route selection advancing from a first route to a second route by either of two conditions: (1) there are no resources available to terminate the call in the first zone; and (2) a lack of response to the directory GK request for such resources.

3. 发明申请

WO2002082722A2 ALTERNATE ROUTING OF VOICE COMMUNICATION IN A PACKET-BASED NETWORK 审中-公开
标题翻译：基于分组网络的语音通信的替代路由
公开(公告)号：WO2002082722A2
公开(公告)日：2002-10-17
申请号：PCT/US2002/011076
申请日：2002-04-08
申请人： GENUITY INCORPORATION , MUSSMAN, Harry, Edward , MCCABE, John, Joseph , MCGUIGAN, David, Frederick , ISRAEL, Robert, Keller , SPOREL, Eric, Richard
发明人： MUSSMAN, Harry, Edward , MCCABE, John, Joseph , MCGUIGAN, David, Frederick , ISRAEL, Robert, Keller , SPOREL, Eric, Richard
IPC分类号： H04L12/00
CPC分类号： H04M7/006 , H04L29/06027 , H04L65/1009 , H04L65/103 , H04L65/104 , H04L65/1069 , H04M15/00
摘要： A method for performing alternate and therefore least cost routing in distributed H.323 Voice over IP (VoIP) networks is provided. With this method, the VoIP network consists of a hierarchy of gatekeeper (GK) functions to provide alternate routing, network element redundancy, and scalability. The alternate routing function is performed by a directory gatekeeper with route selection advancing from a first route to a second route by either of two conditions: (1) there are no resources available to terminate the call in the first zone; and (2) a lack of response to the directory GK request for such resources.
摘要翻译：提供了一种在分布式H.323 IP语音（VoIP）网络中执行交替且因此最低成本路由的方法。通过这种方法，VoIP网络由网守（GK）功能的层次结构组成，提供备用路由，网元冗余和可扩展性。替代路由功能由具有从第一路由前进到第二路由的路由选择的目录网守执行，其中两个条件中的任一个：（1）在第一区域中没有可用于终止呼叫的资源; 和（2）对这种资源的目录GK请求的缺乏响应。

4. 发明申请

WO0189520A3 DEHYDROASCORBIC ACID FORMULATIONS AND USES THEREOF 审中-公开
标题翻译：脱氢胆酸配方及其用途
公开(公告)号：WO0189520A3
公开(公告)日：2002-09-12
申请号：PCT/US0041407
申请日：2000-10-20
申请人： PROGENICS PHARM INC , OLSON WILLIAM C , ISRAEL ROBERT J , BOYD THOMAS A
发明人： OLSON WILLIAM C , ISRAEL ROBERT J , BOYD THOMAS A
IPC分类号： A61K9/08 , A61K31/375 , A61K45/06 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/18 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P9/04 , A61P9/08 , A61P9/10 , A61P19/02 , A61P21/04 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/20 , A61P25/28 , A61P27/12 , A61P29/00 , A61P31/12 , A61P35/00 , A61P39/00 , A61P39/06 , A61P43/00 , A01N1/02
CPC分类号： A61K9/0014 , A61K31/375 , A61K45/06 , A61K47/02 , A61K47/12 , A61K2300/00
摘要： The invention provides improved dehydroascorbic acid compositions and methods for treatment of medical conditions. The dehydroascorbic acid compositions are useful in the treatment of a variety of conditions which benefit from increased dehydroascorbic acid or ascorbic acid concentrations in tissues affected by the conditions.
摘要翻译：本发明提供改进的脱氢抗坏血酸组合物和治疗医学病症的方法。脱氢抗坏血酸组合物可用于治疗由受条件影响的组织中增加的脱氢抗坏血酸或抗坏血酸浓度的各种病症的治疗。

5. 发明申请

WO2004095850A3 SYSTEM AND METHOD FOR IP TELEPHONY PING 审中-公开
标题翻译： IP电话平台的系统与方法
公开(公告)号：WO2004095850A3
公开(公告)日：2005-10-13
申请号：PCT/US2004012018
申请日：2004-04-16
申请人： LEVEL 3 COMMUNICATIONS INC , EICHEN ELLIOT , ISRAEL ROBERT , BELIN EVEGENI , OLSHANSKY ROBERT
发明人： EICHEN ELLIOT , ISRAEL ROBERT , BELIN EVEGENI , OLSHANSKY ROBERT
IPC分类号： H04L12/24 , H04L12/26 , H04M3/22 , H04M3/26 , H04M7/00 , H04L12/66
CPC分类号： H04L65/80 , H04L41/0681 , H04L43/0811 , H04L43/0829 , H04L43/087 , H04L43/10 , H04L65/1069 , H04M3/2227 , H04M3/26 , H04M7/006
摘要： The present invention provides a system and method for establishing the availability of a node to received a voice over internet protocol (VoIP) call. The present invention comprises attempting to establish a VoIP call to a given node that is the target of the VoIP call, determining whether the attempt to establish the VoIP call is successful; and generating an alarm in response to a call failure. Acording to embodiments of the invention, the method may comprise extracting call metrics from a VoIP call that provide information regarding the quality of a VoIP connection and generating an alarm in response to the call metrics falling below a threshold.
摘要翻译：本发明提供一种用于建立节点可用性以接收互联网协议语音（VoIP）呼叫的系统和方法。本发明包括尝试建立对作为VoIP呼叫的目标的给定节点的VoIP呼叫，确定建立VoIP呼叫的尝试是否成功; 并响应于呼叫失败而产生报警。根据本发明的实施例，该方法可以包括从提供关于VoIP连接的质量的信息的VoIP呼叫中提取呼叫指标，并响应于低于阈值的呼叫度量来产生警报。

6. 发明申请

WO2005013541A3 SYSTEM AND METHOD FOR PROVIDING ALTERNATE ROUTING IN A NETWORK 审中-公开
标题翻译：在网络中提供替代路由的系统和方法
公开(公告)号：WO2005013541A3
公开(公告)日：2005-05-26
申请号：PCT/US2004025035
申请日：2004-07-29
申请人： LEVEL 3 COMMUNICATIONS INC , MUSSMAN HARRY E , O'BRIEN JAMES D , SPOREL ERIC R , ISRAEL ROBERT K , BAJ MICHAEL
发明人： MUSSMAN HARRY E , O'BRIEN JAMES D , SPOREL ERIC R , ISRAEL ROBERT K , BAJ MICHAEL
IPC分类号： H04L1/22 , H04L12/28 , H04L29/06 , H04M7/00 , H04Q3/66 , H04L12/26
CPC分类号： H04L65/1043 , H04L1/22 , H04L12/5692 , H04L29/06027 , H04L65/103 , H04L65/104 , H04L65/1069 , H04L65/80 , H04M7/0057 , H04Q3/66 , H04Q2213/13034 , H04Q2213/13138 , H04Q2213/13141 , H04Q2213/13167 , H04Q2213/13389
摘要： Methods and systems are described for performing alternate routing of communications in a network. The system initiates a communication from an origination endpoint in a packet-switched network, such as a VOIP network, to a destination endpoint, and determining, according to selection criteria, whether to route the communication to the destination endpoint using at least a second circuit-switched network, such as the PSTN.
摘要翻译：描述了用于在网络中执行通信的替代路由的方法和系统。系统发起从诸如VOIP网络的分组交换网络中的始发端点到目的地端点的通信，以及根据选择标准确定是否使用至少第二电路将通信路由到目的地端点切换网络，如PSTN。

7. 发明申请

WO2007014114A2 METHODS FOR REDUCING VIRAL LOAD IN HIV-1-INFECTED PATIENTS 审中-公开
标题翻译：减少HIV-1感染患者病毒载量的方法
公开(公告)号：WO2007014114A2
公开(公告)日：2007-02-01
申请号：PCT/US2006/028565
申请日：2006-07-21
申请人： PROGENICS PHARMACEUTICALS, INC. , OLSON, William, C. , MADDON, Paul, J. , PEVEAR, Daniel, C. , ISRAEL, Robert, J. , MURGA, Jose, D.
发明人： OLSON, William, C. , MADDON, Paul, J. , PEVEAR, Daniel, C. , ISRAEL, Robert, J. , MURGA, Jose, D.
IPC分类号： C12Q1/68 , G01N33/53
CPC分类号： A61K39/39 , A61K31/351 , A61K31/4178 , A61K31/46 , A61K31/496 , A61K31/506 , A61K31/551 , A61K31/7072 , A61K38/1709 , A61K38/195 , A61K39/39541 , A61K39/3955 , A61K2039/505 , A61K2039/55511 , C07K16/2866 , C07K2317/24 , C07K2317/76 , C12Q1/701 , A61K2300/00
摘要： This method provides a method for reducing HIV-I viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-I viral load- reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-I -associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-I to CCR5 + CD4 + target cells in the subject. This invention also provides a method for treating a subject infected with HIV-I comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 + cells and (ii) inhibits fusion of HIV-I to the subject's CCR5 + CD4 + cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
摘要翻译：该方法提供了一种减少HIV-1感染的人受试者中的HIV-1病毒载量的方法，其包括以预定间隔向受试者施用有效的HIV-1病毒载量 - 减少剂量的（a）命名为PRO 140的人源化抗体，或（b）抗CCR5受体单克隆抗体。本发明还提供了一种在人类受试者中抑制HIV-1相关疾病的发作或进展的方法，其抑制通过抑制HIV-1与CCR5 + SUP> + 靶细胞。本发明还提供了用于治疗感染HIV-1的受试者的方法，其包括对受试者施用（a）单克隆抗体，所述单克隆抗体（i）结合受试者的CD4 + 细胞和（ii）抑制HIV-1与受试者的CCR5 + CD4 +细胞融合，和（b）非抗体CCR5受体拮抗剂，其量有效对待主题。

8. 发明申请

WO2005013541A2 SYSTEM AND METHOD FOR PROVIDING ALTERNATE ROUTING IN A NETWORK 审中-公开
标题翻译：用于在网络中提供备用路由的系统和方法
公开(公告)号：WO2005013541A2
公开(公告)日：2005-02-10
申请号：PCT/US2004/025035
申请日：2004-07-29
申请人： LEVEL 3 COMMUNICATIONS, INC. , MUSSMAN, Harry E. , O'BRIEN, James D. , SPOREL, Eric R. , ISRAEL, Robert K. , BAJ, Michael
发明人： MUSSMAN, Harry E. , O'BRIEN, James D. , SPOREL, Eric R. , ISRAEL, Robert K. , BAJ, Michael
IPC分类号： H04L
CPC分类号： H04L65/1043 , H04L1/22 , H04L12/5692 , H04L29/06027 , H04L65/103 , H04L65/104 , H04L65/1069 , H04L65/80 , H04M7/0057 , H04Q3/66 , H04Q2213/13034 , H04Q2213/13138 , H04Q2213/13141 , H04Q2213/13167 , H04Q2213/13389
摘要： Methods and systems are described for performing alternate routing of communications in a network. The system initiates a communication from an origination endpoint in a packet-switched network, such as a VOIP network, to a destination endpoint, and determining, according to selection criteria, whether to route the communication to the destination endpoint using at least a second circuit-switched network, such as the PSTN.
摘要翻译：描述了用于在网络中执行通信的替代路由的方法和系统。系统发起从分组交换网络（例如VOIP网络）中的始发端点到目的地端点的通信，并且根据选择标准确定是否使用至少第二电路将通信路由到目的地端点交换网络，如PSTN。

9. 发明申请

WO2006099314A8 USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CONSTIPATION IN TERMINALLY ILL PATIENTS 审中-公开
标题翻译：使用甲基内酯和相关化合物治疗终末期患者的组织
公开(公告)号：WO2006099314A8
公开(公告)日：2006-12-28
申请号：PCT/US2006008935
申请日：2006-03-10
申请人： PROGENICS PHARM INC , ISRAEL ROBERT J
发明人： ISRAEL ROBERT J
IPC分类号： A61K31/485 , A61P1/10
CPC分类号： A61K31/485
摘要： Methods and compositions are provided for treating constipation in terminally-ill patients who are using opioids chronically. Methods include administering a quaternary derivative of noroxymorphone (e.g., methylnaltrexone) to a terminally-ill chronic opioid using patient in an amount sufficient to prevent the occurrence or reoccurrence of constipation.
摘要翻译：提供方法和组合物用于治疗慢性使用阿片样物质的终末期患者的便秘。方法包括使用患者以足以防止便秘的发生或再发生的量向终末期慢性阿片样物质施用去甲吗啡酮（例如甲基纳曲酮）的季衍生物。

10. 发明申请

WO2006099314A1 USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CONSTIPATION IN TERMINALLY ILL PATIENTS 审中-公开
标题翻译：甲基纳曲酮及相关化合物治疗终末期ILL患者的疗效
公开(公告)号：WO2006099314A1
公开(公告)日：2006-09-21
申请号：PCT/US2006/008935
申请日：2006-03-10
申请人： PROGENICS PHARMACEUTICALS, INC. , ISRAEL, Robert, J.
发明人： ISRAEL, Robert, J.
IPC分类号： A61K31/485 , A61P1/10
CPC分类号： A61K31/485
摘要： Methods and compositions are provided for treating constipation in terminally-ill patients who are using opioids chronically. Methods include administering a quaternary derivative of noroxymorphone (e.g., methylnaltrexone) to a terminally-ill chronic opioid using patient in an amount sufficient to prevent the occurrence or reoccurrence of constipation.
摘要翻译：提供方法和组合物用于治疗长期使用阿片样物质的末期病患的便秘。方法包括使用患者的量为足以预防便秘发生或再发的去甲羟吗啡酮的季衍生物（例如甲基纳曲酮）给终末期慢性阿片样物质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式